Description:
A drug used to treat adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma (types of brain tumors) that has an abnormal IDH1 or IDH2 gene. It is used in patients who had a biopsy or surgery to remove the tumor. It is also being studied in the treatment of other types of cancer. Voranigo blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep cancer cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Also called vorasidenib citrate.
